ClinicalTrials.gg
CompletedNCT03503266MT-7117 MBUpdated May 15, 2023

Mass Balance Study With MT-7117

A Phase 1 interventional study of [14C] MT-7117 in Healthy Volunteer, sponsored by Mitsubishi Tanabe Pharma America Inc.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by Mitsubishi Tanabe Pharma America Inc. (part of Tanabe Pharma Corporation) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

This is a single-centre, open-label, mass balance study in healthy male subjects utilising a single oral dose of [14C] MT 7117.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Mass Balance Study with MT-7117
03

In context

Lead sponsor

Mitsubishi Tanabe Pharma America Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Able to provide written to participate in this study after reading the participant information sheet and Informed Consent Form, and after having the opportunity to discuss the study with the Investigator or designee.
    1. Caucasian male subjects aged 30 to 65 years (inclusive) at Screening.
    1. Healthy and free from illness or disease as determined by medical history, physical examination, (ECG), vital signs, laboratory and other tests at Screening and Day -1, unless deemed not by the Investigator or designee.
    1. Body weight of 60 to 110 kg (inclusive) and a (Quetelet index) ranging from 18 to 32 kg/m2 (inclusive) at Screening and Day -1.
    1. Vital signs within the following ranges at Screening and Day -1:

      • Systolic blood pressure: 90 to 140 mmHg
      • Diastolic blood pressure: 50 to 90 mmHg
    1. Subjects and partners agree to use throughout the study, as defined in the Protocol body.
    1. Able to understand, in the Investigator's opinion, the nature of the study and any risks involved in participation and willing to cooperate and comply with the Protocol restrictions and requirements.
    1. Regular daily bowel movements (i.e., production of at least one stool per day).

Exclusion criteria

Exclusion Criteria:

    1. Presence or history of severe adverse reaction or allergy to any medicinal product that is of clinical significance.
    1. Participated in more than three clinical studies of a new chemical entity in the previous year or participated in a clinical study of any IMP within 12 weeks or five half-lives (whichever is longer) before the administration of IMP in this clinical study.
    1. Consumption of any food-supplements, prescribed or over the counter medicine (including herbal and dietary supplements, such as St. John's Wort) during the 7 days (or 14 days if the medicine is a potential enzyme inducer) or five half-lives (whichever is longer) before the administration of IMP and during the study, unless in the opinion of the Sponsor and the Investigator, the medication will not interfere with the objectives of the study or compromise the subject's safety (Note: The use of acetaminophen [2 g/day for up to 3 consecutive days] will be permitted from Screening and during the study).
    1. (in the opinion of the Investigator) endocrine, thyroid, hepatic (including Gilbert's syndrome), respiratory, gastrointestinal or renal disease, diabetes mellitus (type I and II), coronary heart disease, hypertension, or significant history of any psychiatric/psychotic disorder (including anxiety, depression and reactive depression).
    1. Clinically relevant abnormal medical history, physical findings or laboratory values at Screening or Day -1 that could interfere with the objectives of the study or the safety of the subject, as judged by the Investigator.
    1. Subjects with or alanine aminotransferase ≥2 x or above reference range at Screening or Day -1, confirmed by a repeat test at each visit.
    1. Has a positive surface antigen, hepatitis B core antibody, virus antibody, or type 1 (HIV-1) and type 2 (HIV-2) result at Screening.
    1. Clinically significant abnormal 12-lead findings, including subjects with interval using Fridericia's formula (QTcF) of >450 ms, or presence of atrial fibrillation or other significant arrhythmia at Screening or Day -1, confirmed by repeat assessment.
    1. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardise the subject in case of participation in the study. The Investigator should be guided by evidence of any of the following:

      • history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding;
      • history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bowel resection;
      • history or clinical evidence of pancreatic injury or pancreatitis.
    1. Excessive consumption of food or drink containing caffeine, including coffee, tea, cola, energy drinks or chocolates (>5 cups of coffee or equivalent per day).
    1. Consumption of food or drink containing grapefruit, poppy seeds or Seville oranges from 7 days before the administration of the IMP.
    1. Presence or history (in the last 2 years) of alcohol abuse or weekly alcohol intake of more than 28 units (224 g) or a positive urine or breath alcohol test at Screening or Day 1. One unit (8 g) is equivalent to a ½ pint (280 mL) of beer, 1 measure (25 mL) of spirits or 1 small glass (125 mL) of wine.
    1. Presence or history of drug abuse (as defined by [DSM-V] criteria) or a positive urine test for drugs of abuse at Screening or Day -1.
    1. Donation of one or more units of blood (450 mL) within 3 months before the administration of the IMP, or plasma within 7 days prior to Screening, or within 6 weeks prior to Screening or the intention to donate blood within 3 months after the final study visit.
    1. Use of tobacco or nicotine-containing products (snuff, chewing tobacco, cigars, pipes, e cigarettes or nicotine replacement products) within the 3 month period prior to administration of IMP, during the confinement period and until the final study visit, or positive urine cotinine test at Screening or Day -1.
    1. Heavy physical training or excessive exercise (e.g., long distance running, weight lifting or any physical activity to which the subject is not accustomed) from 7 days before the administration of IMP, during the participation in the study and for 7 days prior to any outpatient visit.
    1. Family history of long QT syndrome or Torsades de Pointes.
    1. Subjects with poor peripheral venous access.
    1. Subjects who had a major surgical procedure or significant traumatic injury within 14 days prior to Day -1, or anticipation of the need for major surgery during the study period.
    1. Subjects with \<60 mL/minute (calculated using Cockcroft-Gault formula) at Screening.
    1. History of irritable bowel syndrome or other manifestation of abnormal bowel habit (e.g., diarrhoea, constipation).
    1. Previous exposure to MT-7117 before the administration of IMP in this study.
    1. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C] MT-7117

    14-C MT-7117

    Drug: [14C] MT-7117

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax - maximum observed plasma concentration (plasma and whole blood)

    Time frame: at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.

  2. tmax - time at which Cmax occurs (plasma and whole blood)

    Time frame: at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.

  3. AUC0 t - area under the plasma concentration time curve from time zero to the last measurable concentration (plasma and whole blood)

    Time frame: at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.

  4. AUC0-∞ - area under the plasma concentration-time curve from time zero to infinity (plasma and whole blood)

    Time frame: at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.

  5. t½ - apparent terminal elimination half-life (plasma and whole blood)

    Time frame: at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.

  6. Kel - terminal elimination rate constant (plasma and whole blood)

    Time frame: at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.

  7. CL/F - apparent clearance (plasma and whole blood)

    Time frame: at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.

  8. VZ/F - apparent volume of distribution (plasma and whole blood)

    Time frame: at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.

  9. Total radioactivity in urine and faeces

    Ae (urine), Ae (faeces) and Ae (total): amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined).

    Time frame: Day -1 and up to 168 hours post-dose. If collection is extended up to Day 14: up to 312 hours post-dose.

  10. Total radioactivity in urine and faeces

    %Ae (urine), %Ae (faeces) and %Ae (total): amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined) expressed as a percentage of the dose.

    Time frame: Day -1 and up to 168 hours post-dose. If collection is extended up to Day 14: up to 312 hours post-dose.

Secondary outcomes

  1. Safety and tolerability as measured by incidence of adverse events (AEs) and serious AEs

    Time frame: Up to 14 Days after dosing

07

Study locations

1 site
  • Investigational Centre
    United Kingdom, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in May 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2018
First posted
Apr 19, 2018
StartActual
Mar 23, 2018
Primary completionActual
May 11, 2018
CompletionActual
May 11, 2018
Last update
May 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03503266
Responsible party
Sponsor
First posted
Apr 19, 2018
Start date
Mar 23, 2018
Primary completion
May 11, 2018
Completion
May 11, 2018
Last update
May 15, 2023

Study contacts

General Manager
study director · Mitsubishi Tanabe Pharma Europe Ltd

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion